RSRuofan Shi

Ruofan Shi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ruofan Shi has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Age Acceleration and Mortality Risk Constitute Distinct Dimensions of Organ Aging

    by Rong Na, Chang Shi, Xiaohao Ruan, Ruofan Shi, Ruochen Ma, Zixin Liang, Yao Sun, Chi Yao, Xiangchuan Xu, Xue Li, et al.

    Organ biological aging is highly heterogeneous, yet existing computational clocks typically model it as a single-rate phenomenon. It remains unclear whether chronological age acceleration and mortality risk are driven by shared or distinct biological programs. Here, we established multi-omics, organ-specific aging clocks for 14 organs across 409,206 UK Biobank participants, integrating nuclear magnetic resonance (NMR) metabolomics, Olink proteomics, and clinical phenotypes. By evaluating age acceleration against both organ-specific mortality and all-cause mortality, we demonstrate that age acceleration and mortality risk are divergent dimensions of organ biology with separable phenotypic, molecular, and genetic architectures. Feature-ablation genome-wide association studies revealed three molecular layers underlying these signatures including NMR-dependent, plasma-protein-direct and clinical-biochemistry-mediated, demonstrating that single-platform designs systematically miss complementary biology. This divergence is highlighted by a prostate paradox, where all-cause mortality training entirely obscures the incident prostate cancer signal that the organ-specific mortality clock powerfully recovers. Finally, applying polygenic scores in a non-overlapping validation cohort of 383,227 individuals alongside bidirectional Mendelian randomization and multi-tier gene prioritization, we prioritized 13 candidate genes underlying these distinct aging dimensions. Our findings establish that multi-omics integration combined with organ-specific training captures vital components of organ aging invisible to conventional single-objective clocks. Crucially, this multi-objective framework enables organ-resolved comorbidity risk assessments that traditional competing-risk models obscure, providing a highly translatable foundation for targeted clinical surveillance and actionable, organ-specific interventions.

  • Open Access

    Association of Germline Single Nucleotide Polymorphisms in Steroid Hormone Metabolism Pathway With Androgen Deprivation Therapy Prognosis of Prostate Cancer in Chinese Population

    by Ruofan Shi, Xiaohao Ruan, Qijun Du, Tsun Tsun Stacia Chun, Da Huang, Kuen Chan, Yuguang Philip Wu, Tsz Yeung Kam, Danfeng Xu, Rong Na

    Background: Single nucleotide polymorphisms (SNPs) located in the genes participating in the steroid hormone metabolism pathway may influence the outcomes of androgen deprivation therapy (ADT) in prostate cancer (PCa) patients, but findings on the Chinese population remain limited. Methods: A multicentric cohort of 301 Chinese PCa patients receiving first‐line ADT was enrolled. Germline SNPs located in 62 steroid hormone metabolism‐related genes were analyzed for associations with time to ADT failure using multivariate Cox regression. Important expression quantitative trait loci (eQTLs) were discovered. Results: Four SNPs were significantly associated with time to ADT failure: rs36119043 in AKR1D1 (hazard ratio, HR = 2.02, 95% confidence interval, 95% CI: 1.44–2.85, p = 5.72 × 10 −5 ), rs151155810 in HSD17B12 (HR = 7.87, 95% CI: 2.78–22.30, p = 1.05 × 10 −4 ), rs71179009 in SULT2B1 (HR = 2.16, 95% CI: 1.44–3.22, p = 1.85 × 10 −4 ), rs28609134 in SRD5A3 (HR = 2.50, 95% CI: 1.51–4.15, p = 3.79 × 10 −4 ). Potential causal eQTLs in the LD regions of these SNPs were identified, with significant impacts on AKR1D1 , SULT2B1 , and SRD5A3 expression in diverse tissues. A cumulative risk allele effect was observed: HR = 2.74 (95% CI: 1.86–4.03) under the dominant model and HR = 2.04 (95% CI: 1.63–2.55) under the additive model, with a median survival of 176 months (95% CI: N/A) in noncarrier patients vs. 92 months (95% CI: 65–N/A) in one risk locus‐carriers and 55 months (95% CI: 26–N/A) in two risk loci‐carriers. Conclusions: SNPs in the steroid hormone metabolism pathway can predict time to ADT failure in Chinese PCa patients, supporting their potential role for drug response and pharmacogenomic stratification.

  • Open Access

    Cost–effectiveness analysis of prostate-specific antigen screening in China: a middle-income population-based microsimulation study

    by Jiacheng Liu, Yuanshi Jiao, Yueting Huang, Yongle Zhan, Ruofan Shi, Xiaohao Ruan, Chi Yao, Ruochen Ma, Salida Ali, Tsun Tsun Chun, et al.


  • Open Access

    Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: Protocol for a Pilot Randomized Controlled Trial

    by Yongle Zhan, Xiaohao Ruan, Yishuo Wu, Tsun Tsun Stacia Chun, Chi Yao, Ruofan Shi, Jiacheng Liu, Salida Ali, Ruochen Ma, Da Huang, et al.

    Background: Urothelial carcinoma is one of the most commonly diagnosed cancers worldwide, with a poor 5-year survival rate. As genomics is the backbone of the precision medicine paradigm, the genetic signature in circulating tumor DNA (ctDNA) is emerging as a pivotal biomarker for detecting early-stage cancer and molecular residual disease (MRD). Objective: We aim to evaluate the feasibility and preliminary effects of a ctDNA-based sequencing approach for detecting MRD and guiding adjuvant chemotherapy in postoperative urothelial carcinomas. Methods: We will perform a stratified 2-arm pilot randomized controlled trial in 2 tertiary hospitals in Hong Kong, involving patients with urothelial carcinomas (pT2-4a N0-2 M0) undergoing radical resection. We plan to recruit 20 patients and determine stratification according to their MRD status before randomization. Patients in each stratum (MRD-positive and MRD-negative groups) will be randomly allocated to either a 4-cycle gemcitabine plus cisplatin chemotherapy arm or a standard management arm in a 1:1 ratio. ctDNA MRD will be tested using a personalized next-generation sequencing panel, which is designed based on the individual’s whole exome sequencing results from the operation specimen. The primary outcome is the feasibility of this trial (ie, recruitment, retention, adherence, and completeness). The secondary outcome is treatment-related adverse events. Exploratory outcomes include radiographic disease-free survival, cancer-specific survival, overall survival, ctDNA clearance in patients with ctDNA MRD-positive status, quality of life, fear of cancer recurrence, and cost-effectiveness. Benchmarks for feasibility evaluation are set as (1) ≥20% recruitment response rate, (2) ≤20% loss to follow-up or withdrawal, (3) ≥80% intervention adherence, and (4) ≤20% missing value rate. Each benchmark will be assigned one score, and a total score of 4, 2 to 3, and 0 to 1 will be deemed high, medium, and low feasibility, respectively. Safety evaluations will be presented as numbers and proportions of the adverse events. ANOVA and the Kruskal-Wallis test will be used for continuous outcome variables, whereas the chi-square test and the Fisher exact test will be used for categorical outcome variables. Hazard ratios will be calculated to compare the preliminary treatment effect of the gemcitabine plus cisplatin arm against the standard management arm on survival within each MRD group. Results: This project was funded in February 2024. Patient recruitment started on May 2, 2024. Recruitment and data collection for the trial are ongoing. Data analysis will be performed in mid-2025 and the results of this study are expected to be published in late 2025. Conclusions: Genetic signature in ctDNA is informative for personalized management of postoperative urothelial carcinomas, including personalized treatment and early detection of disease progression. Trial Registration: ClinicalTrials.gov NCT06257017; https://clinicaltrials.gov/study/NCT06257017 International Registered Report Identifier (IRRID): DERR1-10.2196/72597


  • Open Access

    Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: Protocol for a Pilot Randomized Controlled Trial (Preprint)

    by Yongle Zhan, Xiaohao Ruan, Yishuo Wu, Tsun Tsun Stacia Chun, Chi Yao, Ruofan Shi, Jiacheng Liu, Salida Ali, Ruochen Ma, Da Huang, et al.

    BACKGROUND Urothelial carcinoma is one of the most commonly diagnosed cancers worldwide, with a poor 5-year survival rate. As genomics is the backbone of the precision medicine paradigm, the genetic signature in circulating tumor DNA (ctDNA) is emerging as a pivotal biomarker for detecting early-stage cancer and molecular residual disease (MRD). OBJECTIVE We aim to evaluate the feasibility and preliminary effects of a ctDNA-based sequencing approach for detecting MRD and guiding adjuvant chemotherapy in postoperative urothelial carcinomas. METHODS We will perform a stratified 2-arm pilot randomized controlled trial in 2 tertiary hospitals in Hong Kong, involving patients with urothelial carcinomas (pT2-4a N0-2 M0) undergoing radical resection. We plan to recruit 20 patients and determine stratification according to their MRD status before randomization. Patients in each stratum (MRD-positive and MRD-negative groups) will be randomly allocated to either a 4-cycle gemcitabine plus cisplatin chemotherapy arm or a standard management arm in a 1:1 ratio. ctDNA MRD will be tested using a personalized next-generation sequencing panel, which is designed based on the individual’s whole exome sequencing results from the operation specimen. The primary outcome is the feasibility of this trial (ie, recruitment, retention, adherence, and completeness). The secondary outcome is treatment-related adverse events. Exploratory outcomes include radiographic disease-free survival, cancer-specific survival, overall survival, ctDNA clearance in patients with ctDNA MRD-positive status, quality of life, fear of cancer recurrence, and cost-effectiveness. Benchmarks for feasibility evaluation are set as (1) ≥20% recruitment response rate, (2) ≤20% loss to follow-up or withdrawal, (3) ≥80% intervention adherence, and (4) ≤20% missing value rate. Each benchmark will be assigned one score, and a total score of 4, 2 to 3, and 0 to 1 will be deemed high, medium, and low feasibility, respectively. Safety evaluations will be presented as numbers and proportions of the adverse events. ANOVA and the Kruskal-Wallis test will be used for continuous outcome variables, whereas the chi-square test and the Fisher exact test will be used for categorical outcome variables. Hazard ratios will be calculated to compare the preliminary treatment effect of the gemcitabine plus cisplatin arm against the standard management arm on survival within each MRD group. RESULTS This project was funded in February 2024. Patient recruitment started on May 2, 2024. Recruitment and data collection for the trial are ongoing. Data analysis will be performed in mid-2025 and the results of this study are expected to be published in late 2025. CONCLUSIONS Genetic signature in ctDNA is informative for personalized management of postoperative urothelial carcinomas, including personalized treatment and early detection of disease progression. CLINICALTRIAL ClinicalTrials.gov NCT06257017; https://clinicaltrials.gov/study/NCT06257017 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/72597

  • The research of synthesis and bioactivity of the novel indanedione anticoagulant rodenticides

    by Feng Chen, Tong Zhang, Chuang Qu, Jinming Wang, Hua Su, Ruofan Shi, Xingyu Zhu

    Three new anticoagulant rodenticides R1, R2, and R3 were designed. The containing fluorine acute toxicity groups was added to 1,3-indandione derivative. Analysis method of synthesized anticoagulant rodenticides were IR, 1H NMR. Acute bioactivity of the new rodenticides was evaluated, including the coefficient of absorb food and median lethal dose (LD50). Average coefficient of absorbed food for R1 was 0.54 and LD50 of R1 was 2.15 mg/kg. Average coefficient of absorbed food for R2 was 0.59 and the acute oral LD50 of R2 was 2.65 mg/kg. Average feeding coefficient of R3 was 0.68 and the acute oral LD50 of R3 was 3.12 mg/kg. Experiments showed that rat’s death peak was at about 72 h and rodenticides had good characteristics of acute medicine. The LD50 of three new fluoride anticoagulant rodenticides showed that they had good palatability for big white rats, and they had a strong poison effect on rodent. The result of all experiments proved that the synthesis of 1,3-indan diketone used as parent compound of new anticoagulant rodenticides could replace the current 4-hydroxyl coumarin as parent compound of the second-generation anticoagulant rodenticides. 1,3-Indan diketone would be widely used as parent compound of anticoagulant rodenticides.